Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from CanSino Biologics, Inc. Class H ( (HK:6185) ).
CanSino Biologics Inc. announced that its new drug application for the DTcP Infant vaccine has been granted priority review status by the Center for Drug Evaluation, NMPA. This priority review status indicates accelerated resource allocation for the review process, potentially enhancing the company’s competitive position in the vaccine market and benefiting shareholders and stakeholders through expedited access to the vaccine.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, specializing in the development and production of vaccines. The company focuses on providing innovative vaccine solutions, including those targeting infectious diseases, to meet public health needs.
YTD Price Performance: -4.76%
Average Trading Volume: 1,247,971
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$9.74B
For a thorough assessment of 6185 stock, go to TipRanks’ Stock Analysis page.
